rld2202
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 2, 2022 (NCT05481307)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05548543 | Phase 1 | Nov 19, 2022 | Hanmi Pharmaceutical, Jeonbuk National University |
| NCT05548387 | Phase 1 | Oct 1, 2022 | Hanmi Pharmaceutical, Jeonbuk National University |
| NCT05481307 | Phase 1 | Aug 2, 2022 | Hanmi Pharmaceutical, Seoul National University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 3 | 3 | 1 | 2022 |
| Jeonbuk National University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1